Hemogenyx Financial Statements From 2010 to 2025
| HOPHF Stock | USD 1.24 0.00 0.00% |
Check Hemogenyx Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Hemogenyx Pharmaceuticals' main balance sheet or income statement drivers, such as , as well as many indicators such as . Hemogenyx financial statements analysis is a perfect complement when working with Hemogenyx Pharmaceuticals Valuation or Volatility modules.
Hemogenyx |
Hemogenyx Pharmaceuticals Plc Company Current Valuation Analysis
Hemogenyx Pharmaceuticals' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Hemogenyx Pharmaceuticals Current Valuation | 8.17 M |
Most of Hemogenyx Pharmaceuticals' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Hemogenyx Pharmaceuticals Plc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Hemogenyx Pharmaceuticals Plc has a Current Valuation of 8.17 M. This is 99.94% lower than that of the Healthcare sector and 99.82% lower than that of the Biotechnology industry. The current valuation for all United States stocks is 99.95% higher than that of the company.
Hemogenyx Pharmaceuticals Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Hemogenyx Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Hemogenyx Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Hemogenyx Pharmaceuticals competition to find correlations between indicators driving Hemogenyx Pharmaceuticals's intrinsic value. More Info.Hemogenyx Pharmaceuticals Plc is one of the top stocks in return on equity category among its peers. It also is one of the top stocks in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Hemogenyx Pharmaceuticals' earnings, one of the primary drivers of an investment's value.About Hemogenyx Pharmaceuticals Financial Statements
Hemogenyx Pharmaceuticals stakeholders use historical fundamental indicators, such as Hemogenyx Pharmaceuticals' revenue or net income, to determine how well the company is positioned to perform in the future. Although Hemogenyx Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. For example, changes in Hemogenyx Pharmaceuticals' assets and liabilities are reflected in the revenues and expenses on Hemogenyx Pharmaceuticals' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Hemogenyx Pharmaceuticals Plc. Please read more on our technical analysis and fundamental analysis pages.
Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. The company was founded in 2012 and is headquartered in London, the United Kingdom. Hemogenyx Pharmaceuticals operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 10 people.
Currently Active Assets on Macroaxis
| BTC | Bitcoin | |
| TRX | TRON | |
| BNB | Binance Coin | |
| ADA | Cardano | |
| XRP | XRP |
Other Information on Investing in Hemogenyx Pink Sheet
Hemogenyx Pharmaceuticals financial ratios help investors to determine whether Hemogenyx Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Hemogenyx with respect to the benefits of owning Hemogenyx Pharmaceuticals security.